FOXO4-DRI

FOXO4-DRI is a D-retro-inverso (DRI) peptidomimetic designed by Baar et al. (Cell, 2017) to selectively induce apoptosis in senescent cells by disrupting the nuclear FOXO4-p53 protein interaction that maintains senescent cell survival. It is the first published senolytic peptide — a compound capable of selectively killing senescent cells while sparing non-senescent, proliferating cells — and was derived from the p53-interaction domain of FOXO4 using D-retro-inverso chemistry to provide complete protease resistance.

Cellular senescence is an irreversible cell cycle arrest programme triggered by DNA damage, oncogene activation, telomere attrition, and oxidative stress. While senescence evolved as a tumour suppression mechanism — preventing damaged cells from proliferating — senescent cells that persist in tissues secrete the SASP (Senescence-Associated Secretory Phenotype): a complex mixture of pro-inflammatory cytokines (IL-6, IL-8, IL-1alpha), matrix metalloproteinases (MMP-1, MMP-3, MMP-9, MMP-10), growth factors, and chemokines that create a chronic inflammatory microenvironment. Evidence from multiple published studies, including genetic models where senescent cells can be selectively eliminated, has connected elevated senescent cell burden to tissue dysfunction, organismal ageing, and multiple age-related pathologies.

The mechanistic basis for FOXO4-DRI's selectivity is FOXO4's unique role in senescent cell survival. In proliferating cells, FOXO4 is cytoplasmic and functionally inactive for p53 interaction. In senescent cells, chronically elevated DNA damage signalling activates FOXO4 nuclear translocation, where it forms a specific complex with p53. This FOXO4-p53 nuclear complex sequesters p53 in a configuration that blocks its transactivation of pro-apoptotic genes (PUMA/BBC3, NOXA/PMAIP1, BAX) — effectively creating a survival shield for senescent cells despite their chronically active p53. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, releasing p53 to activate the intrinsic apoptosis pathway. Because senescent cells have constitutively high p53 activity (due to persistent DNA damage signalling via the DDR pathway), freed p53 drives robust apoptosis. Proliferating cells, with basal p53 activity, are minimally affected.

The D-retro-inverso design is essential for research utility: all amino acids are D-configuration and the sequence runs C-to-N rather than N-to-C (retro), producing a peptidomimetic that maintains the side-chain presentation geometry of the native L-amino acid sequence while being completely resistant to cellular proteolysis. This stability enables FOXO4-DRI to remain intact throughout cytoplasmic and nuclear transit, maintaining its p53-competing activity.

Senescence confirmation in research models requires multiple markers used in combination: SA-beta-galactosidase activity (enzymatic assay at pH 6.0 with X-gal substrate); p21 (CDKN1A) and p16 (CDKN2A) protein expression by Western blot; gamma-H2AX nuclear foci (persistent DNA damage marker) by immunofluorescence; SAHF (senescence-associated heterochromatin foci) by H3K9me3 staining; and SASP cytokine measurement (IL-6, IL-8 by ELISA in conditioned medium). FOXO4-DRI treatment efficacy is measured by reduction in these markers alongside apoptosis induction (annexin V/PI flow cytometry, caspase-3 cleavage).

Research designs using FOXO4-DRI include: selective senescent cell clearance in fibroblast or epithelial monolayers to examine SASP reduction; tissue explant aging models; comparison with ABT-263 (navitoclax, a Bcl-2/Bcl-xL inhibitor senolytic) to compare mechanistic approaches to senescent cell clearance; and combination with senomorphic compounds (mTOR inhibitors, JAK inhibitors) to compare killing versus SASP suppression strategies.

MW: approximately 1882 Da. Reconstitute in DMSO at 10mM; dilute in aqueous buffer to working concentrations (maximum 0.1% DMSO). Store lyophilised at -20°C, protected from light. For laboratory and analytical research purposes only.